We anticipate a profitable buying opportunity for investors in Merck stock following a 15% decline in July. See why we ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to the first study to show such a benefit in these patients. After five ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Merck KGaA (Merck) has dosed the first subject in a Phase III trial of oral Cladribine to treat generalised myasthenia gravis ...

Merck & Co has received European Commission (EC ... whether express or implied as to its accuracy or completeness. You must ...

The event will pave the way for new commitments from First Ladies, ministers, and the Merck Foundation team to create more ...

What’s next for Akeso and Summit Therapeutics after their cancer immunotherapy outperformed Merck’s Keytruda in a large Phase 3 clinical trial? Who’s the iconoclastic outsider behind Summit ...

In an email, the company pointed out that the majority of patients in LITESPARK-005 received Welireg as their third or fourth-line treatment (87.4%) after being treated with PD-1/L1 inhibitor and ...

Mark Cuban, Barry Diller and James Murdoch among the prominent business world figures backing Kamala Harris' bid for the ...